Clinical Trial News and Research

RSS

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

FDA accepts Labopharm's NDA for formulation of trazodone

Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).

24 Nov 2008

New model predicts risk of recurrence in early stage colon cancer patients

Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.

24 Nov 2008

Artemisinin combination therapies may be almost as effective as treated bednets in preventing malaria

Artemisinin combination therapies (ACTs) could be almost as effective in reducing transmission of malaria as insecticide-treated bednets (ITNs) in areas of low transmission, a study based on data from Tanzania has found. In high transmission areas, long-acting antimalarial regimens may be needed to achieve significant transmission reductions.

24 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

FDA approves Banzel (rufinamide) for Lennox-Gastaut syndrome

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.

20 Nov 2008

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008

XTL Biopharmaceuticals announces results from Bicifadine in diabetic neuropathic pain trial

XTL Biopharmaceuticals Ltd. has announced the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain.

19 Nov 2008

Regular religious service attendance reduces risk of death by 20 percent

A study published by researchers at Yeshiva University and its medical school, Albert Einstein College of Medicine, strongly suggests that regular attendance at religious services reduces the risk of death by approximately 20 percent.

19 Nov 2008

Metabolex announces positive results from phase 2 trial of MBX-8025

The Phase 2 study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor(R)), over an 8-week treatment period.

19 Nov 2008

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.

19 Nov 2008

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

19 Nov 2008

Common ADHD drugs do not cause genetic damage in children

In contrast to recent findings, two of the most common medications used to treat attention deficit hyperactivity disorder (ADHD) do not appear to cause genetic damage in children who take them as prescribed, according to a new study by researchers at the National Institutes of Health (NIH) and Duke University Medical Center.

19 Nov 2008

Trial of Gore-tex-type material to stop strokes

A study is under way at Rush University Medical Center using a small, soft-patch device made of a Gore-tex-type material - often used to make durable outerwear - to close a common hole found in the heart called a patent foramen ovale (PFO) in order to prevent recurrent strokes and transient ischemic attacks (TIAs) in adults.

18 Nov 2008

New imaging technique tracks cancer-killing cells over prolonged period

Coaxing a patient's own cells to hunt down and tackle infected or diseased cells is a promising therapeutic approach for many disorders.

18 Nov 2008

Medicsight seeks FDA 510(k) clearance to market ColonCAD software in the U.S.

Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S.

18 Nov 2008

Ginkgo biloba does nothing for dementia, Alzheimer's

One of the most widely used herbal supplements for improving memory and cognition has no impact on the development of dementia or Alzheimer's disease, according to new results from a $30 million, multi-center study.

18 Nov 2008

Two common cancer drugs prevent, reverse type 1 diabetes

Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco.

18 Nov 2008

Ginkgo's benefits for cognitive decline treatment supported by scientific research

A vast body of research supports numerous health benefits for ginkgo extracts, particularly for treating various symptoms and conditions associated with declining cognitive performance and poor circulation, says the American Botanical Council, an independent nonprofit research and education organization.

18 Nov 2008